Heterocyclic compounds as PRMT5 inhibitors

US11459338B2 · kind B2 · utility

Assignee

• JUBILANT EPISCRIBE LLC · US

Inventors

• Saravanan Vadivelu · Bengaluru, IN
• Sridharan Rajagopal · Bengaluru, IN
• Raghunadha Reddy Burri · Kanchinakote, IN
• Shivani Garapaty · Kanchinakote, IN
• Dhanalakshmi Sivanandhan · Noida, IN
• Manish Kumar Thakur · Kanchinakote, IN
• Tamizharasan Natarajan · Kanchinakote, IN
• Indu N Swamy · Kanchinakote, IN
• Nagendra Nagaraju · Kanchinakote, IN
• Subramaniam Kanagaraj · Kanchinakote, IN
• Zainuddin MOHD · Kanchinakote, IN
• Sayantani Sarkar · Kanchinakote, IN
• Swapan Kumar Samanta · Kanchinakote, IN
• Hariprakash · Noida, IN

Key dates

• Filing date: Nov 23, 2018
• Grant date: Oct 4, 2022
• Expiry date: Nov 23, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D498/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The compounds of Formula I, Formula Ia, and Formula Ib are described herein along with their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof. These compounds inhibit PRMT5 and are useful as therapeutic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, schizophrenia, Alzheimer's disease, Parkinson's disease and the like.